Jefferies Financial Group assumed coverage on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a report issued on Monday, Benzinga reports. The firm issued a buy rating and a $28.00 target price on the stock. Jefferies Financial Group also issued estimates for Milestone Pharmaceuticals’ Q2 2019 earnings at ($0.29) EPS, Q3 2019 earnings at ($0.31) EPS, Q4 2019 earnings at ($0.34) EPS, FY2019 earnings at ($1.80) EPS, FY2020 earnings at ($1.43) EPS, FY2021 earnings at ($1.33) EPS, FY2022 earnings at ($2.38) EPS and FY2023 earnings at ($2.11) EPS.
Several other brokerages have also recently issued reports on MIST. Cowen started coverage on Milestone Pharmaceuticals in a report on Monday. They issued an outperform rating and a $32.00 target price for the company. Piper Jaffray Companies started coverage on Milestone Pharmaceuticals in a report on Monday. They issued an overweight rating and a $26.50 target price for the company. Five investment analysts have rated the stock with a buy rating, Milestone Pharmaceuticals currently has a consensus rating of Buy and a consensus target price of $30.10.
Shares of NASDAQ:MIST opened at $19.84 on Monday. Milestone Pharmaceuticals has a 52-week low of $15.09 and a 52-week high of $22.13.
In related news, major shareholder Rtw Investments, Lp bought 666,667 shares of the company’s stock in a transaction on Thursday, May 9th. The stock was bought at an average cost of $15.00 per share, for a total transaction of $10,000,005.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Holdings A/S Novo bought 333,333 shares of the company’s stock in a transaction on Monday, May 13th. The stock was bought at an average price of $15.00 per share, with a total value of $4,999,995.00. The disclosure for this purchase can be found here.
Milestone Pharmaceuticals Company Profile
Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.
Featured Article: What is the Gross Domestic Product (GDP)?
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.